EU/3/06/375

Table of contents

About

On 22 May 2006, orphan designation (EU/3/06/375) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for nilotinib for the treatment of chronic myeloid leukaemia.

Nilotinib has been authorised in the EU as Tasigna since 19 November 2007.

The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.

Key facts

Active substance
nilotinib
Medicine name
Tasigna
Disease / condition
Treatment of chronic myeloid leukaemia
Date of decision
22/05/2006
Outcome
Positive
Orphan decision number
EU/3/06/375

Sponsor's contact details

Novartis Europharm Limited
Vista Building
Elm Park
Merrion Road
Dublin 4
Tel. +41 61 324 11 11 (Switzerland)
E-mail: orphan.enquiries@novartis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating